Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

ClinicalTrials.gov ID: NCT02267746

Public ClinicalTrials.gov record NCT02267746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Safety and Therapeutic Equivalence of a Generic Tazarotene Foam 0.1%(Actavis) and the Reference Listed Fabior™(Tazarotene Foam, 0.1%) (Stiefel Laboratories, Inc.) in Treatment of Subjects With Acne Vulgaris

Study identification

NCT ID
NCT02267746
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Actavis Inc.
Industry
Enrollment
893 participants

Conditions and interventions

Conditions

Interventions

  • Tazarotene (Fabior™) Drug
  • Tazarotene (Actavis) Drug
  • Vehicle foam Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 40 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2014
Primary completion
Aug 31, 2014
Completion
Aug 31, 2014
Last update posted
Jun 11, 2020

2014

United States locations

U.S. sites
14
U.S. states
5
U.S. cities
11
Facility City State ZIP Site status
Not listed Encino California 91436
Center for Dermatology Clinical Research Fremont California 94538
Moore Clinical Research Brandon Florida 33511
LCC Medical Research Institute Miami Florida 33126
International Dermatology Research Miami Florida 33144
FXM Research Corp Miami Florida 33175
FXM Research Miramar Miramar Florida 33027
Moore Clinical Research Tampa Florida 33609
Moore Clinical Research Tampa Florida 33618
Atlantic Clinical Research Collaborative Wellington Florida 33414
Omega Medical Research Warwick Rhode Island 02886
Research Across America Dallas Texas 75234
Research Across America Plano Texas 75093
Dermatology Research Center Salt Lake City Utah 84117

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02267746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 11, 2020 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02267746 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →